EquitySector - HealthcareVery High Risk
Regular
NAV (17-Apr-25)
Returns (Since Inception)
Fund Size
₹1,634 Cr
Expense Ratio
2.10%
ISIN
INF179KC1HL7
Minimum SIP
₹100
Exit Load
1.00%
Inception Date
04 Oct 2023
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+27.74%
+17.55% (Cat Avg.)
Since Inception
+34.86%
— (Cat Avg.)
Equity | ₹1,563.2 Cr | 95.66% |
Others | ₹44.5 Cr | 2.72% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹193.4 Cr | 11.84% |
Divi's Laboratories Ltd | Equity | ₹139.71 Cr | 8.55% |
Cipla Ltd | Equity | ₹117.44 Cr | 7.19% |
Lupin Ltd | Equity | ₹88.67 Cr | 5.43% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹80.22 Cr | 4.91% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹66.05 Cr | 4.04% |
Glenmark Pharmaceuticals Ltd | Equity | ₹60.68 Cr | 3.71% |
Torrent Pharmaceuticals Ltd | Equity | ₹59.26 Cr | 3.63% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹57.78 Cr | 3.54% |
Eris Lifesciences Ltd Registered Shs | Equity | ₹54.1 Cr | 3.31% |
Aurobindo Pharma Ltd | Equity | ₹53.76 Cr | 3.29% |
Ipca Laboratories Ltd | Equity | ₹53.26 Cr | 3.26% |
Treps - Tri-Party Repo | Cash - Repurchase Agreement | ₹49.83 Cr | 3.05% |
Wockhardt Ltd | Equity | ₹48.9 Cr | 2.99% |
Vijaya Diagnostic Centre Ltd | Equity | ₹42.97 Cr | 2.63% |
Alkem Laboratories Ltd | Equity | ₹41.35 Cr | 2.53% |
Gland Pharma Ltd | Equity | ₹41.24 Cr | 2.52% |
Piramal Pharma Ltd | Equity | ₹39.44 Cr | 2.41% |
Metropolis Healthcare Ltd | Equity | ₹36.89 Cr | 2.26% |
Ami Organics Ltd | Equity | ₹32.73 Cr | 2.00% |
Global Health Ltd | Equity | ₹30.27 Cr | 1.85% |
Fortis Healthcare Ltd | Equity | ₹29.28 Cr | 1.79% |
Laxmi Dental Ltd | Equity | ₹28.69 Cr | 1.76% |
Bajaj Healthcare Limited - Prefential Issue | Preferred Stock | ₹26.37 Cr | 1.61% |
Suven Pharmaceuticals Ltd | Equity | ₹25.1 Cr | 1.54% |
Jubilant Pharmova Ltd | Equity | ₹21.48 Cr | 1.31% |
Ajanta Pharma Ltd | Equity | ₹20.34 Cr | 1.24% |
Pfizer Ltd | Equity | ₹19.75 Cr | 1.21% |
Dr Reddy's Laboratories Ltd | Equity | ₹19.63 Cr | 1.20% |
Sai Life Sciences Ltd | Equity | ₹19.36 Cr | 1.18% |
Zydus Lifesciences Ltd | Equity | ₹17.52 Cr | 1.07% |
Medi Assist Healthcare Services Ltd | Equity | ₹16.94 Cr | 1.04% |
Bajaj Healthcare Ltd | Equity | ₹6.99 Cr | 0.43% |
Net Current Assets | Cash | ₹-5.33 Cr | 0.33% |
Large Cap Stocks
33.47%
Mid Cap Stocks
26.17%
Small Cap Stocks
34.27%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹1,530.47 Cr | 93.66% |
Basic Materials | ₹32.73 Cr | 2.00% |
Standard Deviation
This fund
--
Cat. avg.
16.77%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.75
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.30
Higher the better
Since October 2023
Since October 2023
ISIN INF179KC1HL7 | Expense Ratio 2.10% | Exit Load 1.00% | Fund Size ₹1,634 Cr | Age 1 year 6 months | Lumpsum Minimum ₹100 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Bajaj Finserv Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹307.40 Cr | - |
Bajaj Finserv Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹307.40 Cr | - |
PGIM India Healthcare Fund Direct Growth Very High Risk | 0.7% | 0.0% | ₹104.18 Cr | - |
PGIM India Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹104.18 Cr | - |
WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹303.62 Cr | 26.8% |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹303.62 Cr | 29.0% |
DSP Nifty Healthcare ETF Regular Growth Very High Risk | 0.2% | - | ₹9.77 Cr | 15.8% |
Kotak Healthcare Fund Direct Growth Very High Risk | 0.8% | 0.0% | ₹411.54 Cr | 16.3% |
Kotak Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹411.54 Cr | 14.4% |
HDFC Pharma and Healthcare Fund Regular Growth Very High Risk | 2.1% | 1.0% | ₹1634.08 Cr | 27.7% |
Total AUM
₹7,00,201 Cr
Address
“HUL House”, 2nd Floor, Mumbai, 400 020
Your principal amount will be at Very High Risk
EquitySector - HealthcareVery High Risk
Regular
NAV (17-Apr-25)
Returns (Since Inception)
Fund Size
₹1,634 Cr
Expense Ratio
2.10%
ISIN
INF179KC1HL7
Minimum SIP
₹100
Exit Load
1.00%
Inception Date
04 Oct 2023
Your principal amount will be at Very High Risk
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+27.74%
+17.55% (Cat Avg.)
Since Inception
+34.86%
— (Cat Avg.)
Equity | ₹1,563.2 Cr | 95.66% |
Others | ₹44.5 Cr | 2.72% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹193.4 Cr | 11.84% |
Divi's Laboratories Ltd | Equity | ₹139.71 Cr | 8.55% |
Cipla Ltd | Equity | ₹117.44 Cr | 7.19% |
Lupin Ltd | Equity | ₹88.67 Cr | 5.43% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹80.22 Cr | 4.91% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹66.05 Cr | 4.04% |
Glenmark Pharmaceuticals Ltd | Equity | ₹60.68 Cr | 3.71% |
Torrent Pharmaceuticals Ltd | Equity | ₹59.26 Cr | 3.63% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹57.78 Cr | 3.54% |
Eris Lifesciences Ltd Registered Shs | Equity | ₹54.1 Cr | 3.31% |
Aurobindo Pharma Ltd | Equity | ₹53.76 Cr | 3.29% |
Ipca Laboratories Ltd | Equity | ₹53.26 Cr | 3.26% |
Treps - Tri-Party Repo | Cash - Repurchase Agreement | ₹49.83 Cr | 3.05% |
Wockhardt Ltd | Equity | ₹48.9 Cr | 2.99% |
Vijaya Diagnostic Centre Ltd | Equity | ₹42.97 Cr | 2.63% |
Alkem Laboratories Ltd | Equity | ₹41.35 Cr | 2.53% |
Gland Pharma Ltd | Equity | ₹41.24 Cr | 2.52% |
Piramal Pharma Ltd | Equity | ₹39.44 Cr | 2.41% |
Metropolis Healthcare Ltd | Equity | ₹36.89 Cr | 2.26% |
Ami Organics Ltd | Equity | ₹32.73 Cr | 2.00% |
Global Health Ltd | Equity | ₹30.27 Cr | 1.85% |
Fortis Healthcare Ltd | Equity | ₹29.28 Cr | 1.79% |
Laxmi Dental Ltd | Equity | ₹28.69 Cr | 1.76% |
Bajaj Healthcare Limited - Prefential Issue | Preferred Stock | ₹26.37 Cr | 1.61% |
Suven Pharmaceuticals Ltd | Equity | ₹25.1 Cr | 1.54% |
Jubilant Pharmova Ltd | Equity | ₹21.48 Cr | 1.31% |
Ajanta Pharma Ltd | Equity | ₹20.34 Cr | 1.24% |
Pfizer Ltd | Equity | ₹19.75 Cr | 1.21% |
Dr Reddy's Laboratories Ltd | Equity | ₹19.63 Cr | 1.20% |
Sai Life Sciences Ltd | Equity | ₹19.36 Cr | 1.18% |
Zydus Lifesciences Ltd | Equity | ₹17.52 Cr | 1.07% |
Medi Assist Healthcare Services Ltd | Equity | ₹16.94 Cr | 1.04% |
Bajaj Healthcare Ltd | Equity | ₹6.99 Cr | 0.43% |
Net Current Assets | Cash | ₹-5.33 Cr | 0.33% |
Large Cap Stocks
33.47%
Mid Cap Stocks
26.17%
Small Cap Stocks
34.27%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹1,530.47 Cr | 93.66% |
Basic Materials | ₹32.73 Cr | 2.00% |
Standard Deviation
This fund
--
Cat. avg.
16.77%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.75
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.30
Higher the better
Since October 2023
Since October 2023
ISIN INF179KC1HL7 | Expense Ratio 2.10% | Exit Load 1.00% | Fund Size ₹1,634 Cr | Age 1 year 6 months | Lumpsum Minimum ₹100 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Bajaj Finserv Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹307.40 Cr | - |
Bajaj Finserv Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹307.40 Cr | - |
PGIM India Healthcare Fund Direct Growth Very High Risk | 0.7% | 0.0% | ₹104.18 Cr | - |
PGIM India Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹104.18 Cr | - |
WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹303.62 Cr | 26.8% |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹303.62 Cr | 29.0% |
DSP Nifty Healthcare ETF Regular Growth Very High Risk | 0.2% | - | ₹9.77 Cr | 15.8% |
Kotak Healthcare Fund Direct Growth Very High Risk | 0.8% | 0.0% | ₹411.54 Cr | 16.3% |
Kotak Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹411.54 Cr | 14.4% |
HDFC Pharma and Healthcare Fund Regular Growth Very High Risk | 2.1% | 1.0% | ₹1634.08 Cr | 27.7% |
Total AUM
₹7,00,201 Cr
Address
“HUL House”, 2nd Floor, Mumbai, 400 020
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments